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Abstract
Background: Under compromised biliary regeneration, transdifferentiation of hepatocytes into biliary epithelial
cells (BEC) has been previously observed in rats, upon exposure to BEC-specific toxicant methylene dianiline
(DAPM) followed by bile duct ligation (BDL), and in patients with chronic biliary liver disease. However,
mechanisms promoting such transdifferentiation are not fully understood. In the present study, acquisition of
biliary specific transcription factors by hepatocytes leading to reprogramming of BEC-specific cellular profile was
investigated as a potential mechanism of transdifferentiation in two different models of compromised biliary
regeneration in rats.
Results: In addition to previously examined DAPM + BDL model, an experimental model resembling chronic biliary
damage was established by repeated administration of DAPM. Hepatocyte to BEC transdifferentiation was tracked
using dipetidyl dipeptidase IV (DDPIV) chimeric rats that normally carry DPPIV only in hepatocytes. Following DAPM
treatment, ~20% BEC population turned DPPIV-positive, indicating that they are derived from DPPIV-positive
hepatocytes. New ductules emerging after DAPM + BDL and repeated DAPM exposure expressed hepatocyte-
associated transcription factor hepatocyte nuclear factor (HNF) 4a and biliary specific transcription factor HNF1b. In
addition, periportal hepatocytes expressed biliary marker CK19 suggesting periportal hepatocytes as a potential
source of transdifferentiating cells. Although TGFb1 was induced, there was no considerable reduction in periportal
HNF6 expression, as observed during embryonic biliary development.
Conclusions: Taken together, these findings indicate that gradual loss of HNF4a and acquisition of HNF1b by
hepatocytes, as well as increase in TGFb1 expression in periportal region, appear to be the underlying mechanisms
of hepatocyte-to-BEC transdifferentiation.
Background
Transdifferentiation of the liver epithelial cells (hepato-
cytes and biliary cells) into each other provides a rescue
mechanism in liver disease under the situations where
either cell compartment fails to regenerate by itself. We
have previously reported transdifferentiation of hepato-
cytes into biliary epithelial cells (BEC) both in in vivo
rat model using biliary toxicant 4,4’-methylenedianiline
[diaminodiphenyl methane, (DAPM)] followed by biliary
obstruction induced by bile duct ligation (BDL) [1] and
in vitro using hepatocyte organoid cultures treated with
hepatocyte growth factor (HGF) and epidermal growth
factor (EGF) [2-4]. Other investigators have also demon-
strated hepatocyte-to-BEC transdifferentiation in
hepatocyte cultures [5] and following hepatocyte trans-
plantation in spleen [6]. In humans, chronic biliary liver
diseases (CBLD) characterized by progressive biliary
epithelial degeneration are also known to be associated
with formation of intermediate hepatobiliary cells expres-
sing both hepatocytic and biliary specific markers [7-9].
However, the mechanisms promoting such hepatocyte to
BEC transdifferentiation (or vice versa) are not completely
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understood. In the current study, by repeatedly injuring
biliary cells by minimally toxic dose of DAPM adminis-
tered to rats we established a novel rodent model
resembling CBLD [10]. DAPM selectively injures biliary
cells because toxic metabolites of DAPM are excreted in
bile [10,11].
Orchestrated network of liver-enriched transcription
factors is known to play an important role in pre- and
postnatal liver development as well as in lineage specifi-
cation of hepatoblasts into hepatocytes and BECs
[12,13]. Studies with knockout mice have shown that
hepatocyte nuclear factor (HNF) 1a and HNF4a regu-
late transcription of genes essential for the hepatocytic
lineage [14-16] whereas HNF1b and HNF6 are involved
in development of the gallbladder and bile ducts
[17-19]. In the present study, the expression of hepato-
cyte- and biliary-specific HNFs is examined during
reprogramming of cell lineage during transdifferentia-
tion using DAPM + BDL and repeated DAPM treatment
models.
Gradient of TGFb expression regulated by Onecut
transcription factor HNF6 in ductal plate hepatoblasts
during embryonic liver development is crucial for biliary
differentiation [20]. In the present study, TGFb1 and
HNF6 expression pattern was studied in order to deter-
mine if similar mechanism is recapitulated during hepa-
tocyte to BEC transdifferentiation in the adult liver. The
likely source of hepatocytes capable of functioning as
progenitor cells in the event of compromised biliary
regeneration is investigated by assessing expression of
biliary specific keratin CK19.
To examine if hepatocytes transdifferentiate into bili-
ary epithelium after repeated administration of DAPM,
dipeptidyl peptidase IV (DPPIV) chimeric rats were uti-
lized that normally carry DPPIV-positive population of
only hepatocytes derived from donor DPPIVpositive rats
[21,1-3]. Neither the hepatocytes nor the BECs express
DPPIV in the recipient DPPIV negative rats. Thus,
appearance of biliary epithelial cell clusters positive for
the hepatocyte marker DPPIV provides strong evidence
that BEC are derived from hepatocytes.
Results
Histological and functional bile duct damage after DAPM
administration
Biliary toxicity induced by single administration of
DAPM (50 mg/kg, ip) was monitored by elevations of
serum bilirubin and histopathological observations over a
time course. Maximum biliary injury in terms of serum
bilirubin was apparent by 24 h and consistently stayed
high till 48 h after DAPM (Figure 1A). By day 7, rats
appeared to recover from toxicity as indicated by regres-
sing serum bilirubin levels (Figure 1A). Histopathological
observations revealed biliary cell necrosis as early as 12 h
after DAPM. Necrosis was accompanied by ductular
swelling and inflammation. Some damage to the hepato-
cytes was also observed in the form of bile infarcts. How-
ever, the serum ALT elevations were minimal suggesting
hepatocyte injury by DAPM was secondary (Additional
File 1, Figure S1). Based on the quantitative analysis, 70%
bile ducts were injured by DAPM at 24 h after DAPM.
At 48 h, the bile ducts appeared to be repairing from
injury (Figure 1B). The PCNA analysis indicated that the
biliary cells begin cell division at 48 h and continue till
day 7 (Figure 1C). Based on these findings, we chose to
administer DAPM (50mg/kg, ip) every 2 days for total 3
times in order to inflict repeated biliary injury and simul-
taneously impairing their ability to regenerate themselves.
It should be noted that it is the same dose of DAPM that
was used in our previous study using DAMP + BDL
injury model [1].
Appearance of DPPIV-positive bile ducts after repeated
administration of DAPM
The DPPIV chimeric rats were injected with DAPM at
day 0, day 2, and day 4 (Figure 2A). On day 30 after the
last injection of DAPM the rats were sacrificed and the
liver sections from various lobes were examined for
DPPIV positivity. Before DAPM administration, there
was 40%-50% engraftment of the DPPIV-positive hepa-
tocytes as reported before and none of the biliary cells
were DPPIV-positive (Figure 2B). After DAPM repeated
administration ~20% of the bile ducts turned DPPIV-
positive indicating that they are derived from DPPIV
positive hepatocytes (Figure 2C).
Periportal hepatocyte expression of CK19
CK19 was expressed only in BEC in the normal liver
(Figure 3A). However, after DAPM treatment protocol,
selective periportal hepatocytes were also strongly posi-
tive for CK19 in addition to the BEC (Figure 3B and
3C). Periportal hepatocytic CK19 staining was not uni-
form across the liver lobule. These findings indicate that
the periportal hepatocytes only in the proximity of the
affected biliary cells offer a pool of facultative stem cells
capable of transdifferentiation to biliary cells.
Hepatocyte-associated transcription factor HNF4 a
expression in newly formed biliary ductules
Figure 4 depicts the HNF4a (Figure 4A, B, and 4C) and
CK19 (Figure 4D, E, and 4F) stainings on the serial liver
sections. In the normal rat liver, nuclear HNF4a expres-
sion is observed only in the hepatocytes (Figure 4A).
However, the biliary ductules undergoing repair after
repeated DAPM administration or DAPM + BDL show
incorporation of cells resembling hepatocyte morphol-
ogy that also had HNF4a positive staining (Figure 4B
and 4C, respectively). In Figure 4C and 4F there is a
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panel of ductules in which only some of the cells in a
duct are HNF4a positive and only some of the cells are
CK19 positive (with overlap between some of the cells).
Appearance of biliary-specific transcription factor HNF1b
in hepatocytes intercalated within biliary ductules
HNF1b staining is observed only in the biliary nuclei of
the normal rat liver (Figure 5A) but not in the hepato-
cytes. After DAPM + BDL injury (Figure 5B) and
repeated DAPM toxicity (Figure 5C), many cells which
morphologically appear as hepatocytes are seen interca-
lated within biliary ductules that coexpress HNF4a,
indicating their hepatocytic origin. Many (but not all) of
these cells stain positive for HNF1b (Figure 5B and 5C).
Notice the ductules marked with a thin arrow shown as
an example have HNF1b stain, but are HNF4a- negative
(Figure 5C and 5D). The cells coexpressing HNF1b and
HNF4a appear bigger compared to the normal liver bili-
ary cells, a characteristic of ductular reaction.
Transforming growth factor beta 1 (TGFb1) induction in
the periductular region with no change in HNF6 staining
Compared to controls (Figure 6A), TGFb1 induction
was observed in the region surrounding the biliary duc-
tules after DAPM treatment in both the models under
study (Figure 6B and 6C). TGFb1 Western blot data
indicated increasing trend in both the treatment proto-
cols compared to the controls (Figure 6D), although
DAPM + BDL treatment did not show statistical signifi-
cance from the normal rat liver (NRL) by densitometry.
In the control liver (NRL), nuclear HNF6 staining was
noticed in hepatocytes and biliary cells (Additional File
2, Figure S2, A). However, after DAPM toxicity, no sig-
nificant change in HNF6expression was observed (Addi-
tional File 2, Figure S2, B and C).
Discussion
Mature hepatocytes and BECs contribute to the normal
cell turnover and respond to various types of liver
Figure 1 Biliary injury and regeneration following DAPM toxicity. (A) Serum bilirubin levels indicative of biliary injury after DAPM (50 mg/
kg) administration in F344 rats over a time course. * indicates statistical difference from the 0h control (P ≤ 0.05). (B) Histopathology of the liver
following DAPM toxicity (50 mg/kg) depicted by H&E staining. Arrow points to the biliary injury. (C) Biliary regeneration after DAPM (50 mg/kg)
toxicity depicted by PCNA immunohistochemistry. Brown staining indicates PCNA positive cells. Thin arrow indicates regenerating biliary
ductules. Arrowhead points to the hepatocyte proliferation. Scale bar = 100 μm.
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injuries towards self renewal [22,23]. However, when
their own capacity to proliferate is compromised, both
hepatocytes and BECs can act as facultative stem cells
for each other and compensate for the lost liver tissue
mass [1,23,24]. Presence of the full time uncommitted
stem cells in the liver has been argued historically. Stu-
dies have shown that under compromised hepatocyte
proliferation, biliary cells transdifferentiate into mature
hepatocytes via the “oval cell” (also known as the pro-
genitor cell) pathway [25,26]. When biliary cells are
destroyed by DAPM under compromised hepatocyte
proliferation, the oval cells do not emerge indicating
that biliary cells are the primary source of oval cells
[27,28]. Supporting this notion, hepatocyte-associated
transcription factor expression by bile duct epithelium
and emerging oval cells is observed in the experimental
oval cell activation induced by using 2 acetyl amino-
fluorene (2AAF) + partial hepatectomy (PHx) model
[29] and also in cirrhotic human liver [9,26].
Previously, we demonstrated that hepatocytes can also
transdifferentiate into biliary cells under compromised
biliary proliferation [1-4,9]. Periportal hepatocytes can
transform into BEC when the latter are destroyed by
DAPM and proliferation of biliary epithelium is trig-
gered by bile duct ligation. Under this compromised
biliary proliferation, biliary ducts still appeared and
newly emerging ductules carried hepatocyte marker
DPPIV in the chimeric liver [1]. These findings demon-
strate that hepatocytes serve as facultative stem cells for
the biliary epithelium upon need. In the present study, a
Figure 2 Appearance of DPPIV in bile ducts cells after
repeated DAPM administration (DAPM × 3).(A) Schematic
representation of repeated DAPM administration protocol. DAPM
(50 mg/kg) administered at day 0, 2, and 4 to the DPPIV chimeric
rats. Rats sacrificed at day 30 after the last DAPM injection. DPPIV
staining before (B) and after (C) repeated DAPM administration to
the DPPIV chimeric rats. Arrowheads point to the DPPIV positive bile
ducts. Arrows indicate DPPIV negative bile ducts. The number of
DPPIV positive bile ducts was determined after counting DPPIV
positive bile ductules in liver sections obtained from different lobes
of liver from 3 individual rats separately. None of the bile duct cells
of the DPPIV chimeric rats were positive before DAPM treatment.
~20% bile ducts were noted to be DPPIV positive after DAPM × 3
protocol. Scale bar = 100 μm.
Figure 3 Localization of CK19 following DAPM + BDL or
repeated DAPM treatment (DAPM × 3). (A) Normal rat liver
(NRL), (B) liver from DAPM + BDL treated rat, (C) liver from repeated
DAPM treatment (DAPM x3). Brown color indicates CK19 positive
staining. Arrows indicate bile duct staining. Arrowheads indicate
hepatocytic staining. PV, portal vein; BD, bile duct.
Scale bar = 100 μm.
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novel rodent model of repeated biliary injury was estab-
lished by repeated low dose of DAPM given to rats.
Using this novel model of repeated DAPM treatment
regimen, we demonstrate that hepatocytes undergo
transdifferentiation into biliary epithelium also during
progressive biliary damage. DAPM produces specific
injury to the biliary cells because its toxic metabolites
are excreted in bile [10,11]. In the DPPIV chimeric rats,
bile ducts do not express DPPIV before DAPM adminis-
tration; however, after repeated DAPM treatment ~20%
of the biliary ductules express DPPIV, indicating that
they are derived from hepatocytes. In the chimeric liver,
50% of the hepatocytes are derived from DPPIV +
donor liver.
Therefore, it is possible that DPPIV negative hepato-
cytes also transform into BEC, however cannot be cap-
tured due to lack of DPPIV tag. As per the assumption
~40-50% ducts are derived by transdifferentiation (~20
+ % by DPPIV-positive hepatocytes + ~20 + % by
DPPIV-negative hepatocytes). The rest of the ducts did
not require repair because of lack of injury while part of
the restoration can be due to some biliary regeneration
itself that escaped repeated DAPM injury. After single
DAPM injection, ~70% of the ducts were injured.
DPPIV is expressed only in the hepatocytes in the
chimeric rats before DAPM treatment and therefore
provides strong evidence that DPPIV-positive biliary
cells are originated from hepatocytes after DAPM
treatment. The longest time point studied in the pre-
sent study is 30 days after the DAPM treatment when
biliary restoration is still underway. It is possible that
the biliary cells derived from hepatocytes will suspend
the expression of DPPIV as the restoration process
come to an end.
Figure 4 HNF4a and CK19 immunohistochemistry. Liver sections obtained from normal control rats (NRL, normal rat liver) (A and D), rats
that underwent DAPM + BDL treatment (B and E), or repeated DAPM treatment (DAPM × 3) (C and F). B, E and C, F are serial sections. Brown
nuclear staining indicated HNF4a positive cells in the left panel. Brown cytoplasmic staining in the right panel indicates CK19 positive cells. NRL
bile ducts are HNF4a- negative and CK19 positive. However, after DAPM + BDL and DAPM × 3 treatment bile ducts turn HNF4a positive along
with CK19. In addition, periportal hepatocytes also turn positive for CK19 after BDL + DAPM and DAPM × 3 treatment. PV, portal vein; BD, bile
duct. Scale bar = 100 μm.
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It can be argued that the biliary cells from the donor
liver are the source of new biliary cells observed in the
chimeric liver. However, after collagenase perfusion of
the donor liver only <5% contamination of small admix-
ture of nonparenchymal cells including biliary, stellate,
endothelial, and other cell types was noticed as in rou-
tine hepatocyte preparations. In addition, the chimeric
rats are treated with DAPM that targets biliary cells spe-
cifically. Therefore it is unlikely that newly appearing
biliary cells originate from the very small if any biliary
contamination engrafted in the chimeric liver. In the
chimeric rats, after a thorough examination, not a single
DPPIV-positive bile duct epithelial cell was observed in
total 45 portal triads examined in the sections taken
randomly. DPPIV positive biliary cells are observed in
the chimeric liver only after the DAPM treatment
regimen.
During liver development both hepatocytes and BECs
differentiate from hepatoblasts. The lineage-specific
differentiation is regulated by cell-specific gene expres-
sion in turn controlled primarily by distinct sets of tran-
scription factors [30,31]. Altered patterns of cell
specificity in the expression of the transcription factors
between hepatocytes and BECs has been observed under
severe hepatic necrosis and chronic biliary disease in
human patients [9,26] as well as in experimental condi-
tions of 2AAF + PHx treatment [29]. In the present
study, expression of the hepatocyte-specific transcription
factor HNF4a was observed in the newly repairing duc-
tules after DAPM + BDL and repeated DAPM injury.
The newly repaired biliary ductules showed appearance
of hepatocyte-like cells carrying HNF4a expression. It is
interesting to note that the level of the HNF4a expres-
sion in repairing ductular cells was lower compared to
normal hepatocytes suggesting its gradual loss during
reprogramming towards biliary phenotype.
Consistent with that notion, HNF4a expressing ductular
cells also expressed HNF1b, a BEC-specific transcription
Figure 5 HNF1b and HNF4a immunohistochemistry on serial liver sections. (A) normal control rats (NRL, normal rat liver), (B) rats that
underwent DAPM + BDL treatment, or (C) repeated DAPM treatment (DAPM × 3). HNF1b and HNF4a coexpressing cells are pointed by an
arrow. HNF1b positive but HNF4a negative bile ducts pointed by circles. PV, portal vein; BD, bile duct. Scale bar = 100 μm.
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factor. Specific inactivation of Hnf1b gene in hepatocytes
and bile duct cells using the Cre/loxP system results in
abnormalities of the gallbladder and intrahepatic bile
ducts, suggesting an essential function of Hnf1b in bile
duct morphogenesis [17]. Gain of expression of HNF1b by
the hepatocytes normally expressing HNF4a indicates
switch to the biliary specification of these cells.
In order to examine if the mechanisms that govern the
differentiation of hepatoblasts into BECs are recapitulated
during transdifferentiation of mature hepatocytes into
BECs, expression of TGFb1 and Onecut factor HNF6
were assessed. During liver embryogenesis, a gradient of
TGFb signaling has been shown to control ductal plate
hepatoblasts differentiation [20]. High TGFb1 signaling is
observed near the portal vein and is considered responsi-
ble for differentiation of hepatoblasts into biliary cells. The
Onecut transcription factor HNF6, not expressed in the
immediate periportal hepatoblasts inhibits TGFb signaling
in the parenchyma, and this allows normal hepatocyte dif-
ferentiation. In the present study, an induction of TGFb1
was observed in the hepatocytes the area surrounding the
repairing biliary ductules, reminiscent of the changes seen
in embryonic development. However, HNF6 immunohis-
tochemistry did not reveal significant changes after DAPM
treatment in both the models under study. TGFb1 induc-
tion was also observed in the in vitro hepatocyte organoid
cultures undergoing biliary transdifferentiation [4].
Recently, TGFb1-treated fetal hepatocytes were found to
behave as liver progenitors and also gain expression of
CK19 [24]. The data from our study suggest that TGFb1
signaling can lead to transdifferentiation without any
changes in the HNF6 expression in the adult liver upon
need. It is possible that other transcription factors like
OC-2 known to have overlapping target genes of HNF6
[32] may be responsible for the TGFb1 increase in the
periportal hepatocytes.
The periportal hepatocytes expressed CK19 after
DAPM challenge with or without BDL pointing to the
source of the likely pool of hepatocytes capable of
undergoing transdifferentiation. These results are also
consistent with our previous findings indicating that
subpopulation of periportal hepatocytes represents the
progenitor pool from which biliary cells may emerge in
situations of compromised biliary proliferation [1].
Figure 6 TGFb1 immunohistochemistry. Induction of TGFb1 in the periportal region after DAPM + BDL (B) and DAPM × 3 treatment (C) was
observed compared to NRL (A). Western blot analysis of TGFb1 after DAPM + BDL and DAPM × 3 treatment using liver whole cell lysates.
*P ≤ 0.05. Scale bar = 100 μm.
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Taken together the findings from this study indicate
that the hepatocytes constitute facultative stem cells
for the biliary cells capable of repairing liver histology
when the classic biliary regeneration fails. The find-
ings also suggest that subpopulations of hepatocytes
in periportal region may have a higher tendency to
function as facultative stem cells compared to other
cells of their kind, even though they function as hepa-
tocytes under normal circumstances. The exact mole-
cular mechanisms that govern interchange in
expression of cell-specific HNFs remain to be eluci-
dated. Our earlier study with hepatocyte organoid
cultures point to the role of HGF and EGF in hepato-
biliary transdifferentiation [4]. Via AKT independent
PI3 kinase pathway, HGF and EGF promote hepato-
cyte to BEC transdifferentiation [4]. It is also known
that Foxo transcription factors are regulated by the
PI3 kinase/AKT pathway [33]. It is possible that simi-
lar signaling occurs through HGF and/or EGF via PI3
kinase regulating expression of HNF transcription fac-
tors that in turn lead to transdifferentiation. Overall,
understanding of transdifferentiation of native hepato-
cytes and BECs may prove to be pivotal in cellular
therapy against liver diseases.
Conclusions
Under compromised biliary regeneration, transdifferen-
tiation of hepatocytes into biliary cells provides a rescue
mechanism. Periportal hepatocytes undergoing transdif-
ferentiation gradually loose the expression of hepatocyte
master regulator HNF4a and acquire HNF1b that shifts
cellular profile towards biliary lineage. An increase in
TGFb1 expression in periportal region also appears to




Collagenase for hepatocyte isolation was obtained from
Boehringer Mannheim (Mannheim, Germany). General
reagents and 4,4’-Methylenedianiline (DAPM) were
obtained from Sigma Chemical Co. (St. Louis, MO). Pri-
mary antibodies used are: CK19 (Dako Corp; 1:100),
HNF4a (Santa Cruz; 1:50), HNF6 (Santa Cruz; 1:50),
HNF1b (Santa Cruz; 1:100), TGFb1 (Santa Cruz; 1:200).
Biotinylated secondary antibodies were obtained from
Jackson Laboratories. Target retrieval solution was
obtained from Dako Corp. ABC kit and diaminobenzi-
dine (DAB) kit were from Vector Laboratories.
Animals
DPPIV positive Fisher 344 male rats were obtained from
Charles River Laboratories (Frederick, MD). DPPIV
negative Fisher 344 male rats were obtained from
Harlan (Indianapolis, IN). The animal husbandry and all
procedures performed on the rats employed for these
studies were approved under the IACUC protocol
#0507596B-2 and conducted according to National
Institute of Health guidelines.
Generation of rats with chimeric livers
DPPIV chimeric livers were generated as previously
described [3,21]. Briefly, male DPPIV negative Fisher rats
(200 g) were given two intraperitoneal injections of retro-
rsine (30 mg/kg), dissolved in water. The injections were
given 15 days apart. A month after the last injection, the
rats were subjected to PHx. During the PHx operation, the
rats were also injected directly into the portal circulation
(via a peripheral branch of the superior mesenteric vein)
with 3.5 million hepatocytes isolated from DPPIV positive
male Fisher rats (200 g). The animals were left to recover
and were not subjected to any other experimental proce-
dures for the next 3 months. Assessment of the degree of
engraftment was made under direct microscopic observa-
tion of sections from the chimeric livers, stained for
DPPIV. The percentage of DPPIV positive and negative
cells was estimated at 40× magnification in optic fields that
included at least one portal triad and one central vein. The
percentage of DPPIV-positive cells varied from one lobule
to another. The range of engraftment per optic field (as
defined above) within each animal varied from 30% to 60%.
Treatment with DAPM
Biliary toxicant DAPM (50 mg/kg, dissolved in DMSO
at a concentration of 50 mg/ml) was injected intraperi-
toneally to either DPPIV chimeric or DPPIV positive
male Fisher 344 rats every 2 days. In the pilot study,
bile duct injury after single injection of DAPM was at
its peak at 24 and 48 h after treatment (Figure 1A, B)
while PCNA analysis indicated that the biliary cells
begin cell division at 48 h (Figure 1C). Based on these
findings, we chose to administer DAPM (50 mg/kg, ip)
every 2 days. This treatment was continued for total 3
times and the rats were sacrificed at day 30 after the
last DAPM injection (Figure 2A). The livers were har-
vested and utilized for DPPIV histochemistry.
Additional two groups of normal rats ware given
either intraperitoneal injection of 50 mg DAPM/kg
every two days for 3 times (DAPM × 3) or single
DAPM injection (50 mg DAPM/kg) two days before the
bile duct ligation (DAPM+BDL). At the end of 30 days
after the last treatment, rats were sacrificed Blood was
collected for serum analysis. Livers were harvested for
further analysis.
Bile duct ligation
Bile duct ligation was performed as previously described
[3]. Briefly, the animals were subjected to a mid-abdominal
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incision 3 cm long, under general anesthesia. The com-
mon bile duct was ligated in two adjacent positions
approximately 1 cm from the porta hepatis. The duct was
then severed by incision between the two sites of ligation.
Immunohistochemistry
Paraffin-embedded liver sections (4 μm thick) were used
for immunohistochemical staining. For HNF4a and
HNF6 staining, antigen retrieval was achieved by steam-
ing the slides 60 minutes in preheated target retrieval
solution (Dako Corporation). For CK19 staining the
slides were steamed for 20 minutes in high pH target
retrieval solution (Dako Corporation) before blocking.
For TGFb1 staining no antigen retrieval was necessary.
The tissue sections were blocked in blue blocker for 20
minutes followed by incubation with pertinent primary
antibody overnight at 4°C. The primary antibody was
then linked to biotinylated secondary antibody followed
by routine avidin-biotin complex method. Diaminoben-
zidine was used as the chromogen, which resulted in a
brown reaction product.
Additional material
Additional file 1: Serum ALT levels in F344 rats. Serum ALT levels
after DAPM (50 mg/kg) administration in F344 rats over a time course,
where * indicates statistical difference from the 0h control (P ≤ 0.05).
Additional file 2: HNF6 immunohistochemistry on liver sections. (A)
normal control rats (NRL, normal rat liver), (B) rats that underwent DAPM
+ BDL treatment, or (C) repeated DAPM treatment (DAPM × 3). Brown
nuclear staining indicates HNF6 positive staining. No appreciable
variation in HNF6 expression was noticed in the treatment versus control
groups. Scale bar = 100 μm.
Author details
1Department of Pathology, School of Medicine, University of Pittsburgh
School of Medicine, Pittsburgh, PA 15261, USA. 2Department of
Pharmacology, Toxicology, and Therapeutics, University of Kansas Medical
Center, Kansas City, KS 66160, USA.
Authors’ contributions
PL and WB conducted the animal studies, PL and AO performed the
immunohistochemical stainings, PL and UA collected tissues and performed
Western blotting, PL wrote the manuscript, UA reviewed the manuscript, GM
designed the study, examined histological and immunohistochemical
stainings, and reviewed the manuscript. All the authors have read and
approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 25 May 2010 Accepted: 2 December 2010
Published: 2 December 2010
References
1. Michalopoulos GK, Bowen WC, Mule K, Stolz DB: Histological organization
in hepatocyte organoid cultures. Am J Pathol 2001, 159:1877-1887.
2. Michalopoulos GK, Bowen WC, Mulè K, Lopez-Talavera JC, Mars W:
Hepatocytes undergo phenotypic transformation to biliary epithelium in
organoid cultures. Hepatology 2002, 36:278-283.
3. Michalopoulos GK, Barua L, Bowen WC: Transdifferentiation of rat
hepatocytes into biliary cells after bile duct ligation and toxic biliary
injury. Hepatology 2005, 41:535-544.
4. Limaye PB, Bowen WC, Orr AV, Luo J, Tseng GC, Michalopoulos GK:
Mechanisms of hepatocyte growth factor-mediated and epidermal
growth factor-mediated signaling in transdifferentiation of rat
hepatocytes to biliary epithelium. Hepatology 2008, 47:1702-1713.
5. Nishikawa Y, Doi Y, Watanabe H, Tokairin T, Omori Y, Su M, Yoshioka T,
Enomoto K: Transdifferentiation of mature rat hepatocytes into bile duct-
like cells in vitro. Am J Pathol 2005, 166:1077-1088.
6. Watanabe H, Hata M, Terada N, Ueda H, Yamada N, Yamanegi K,
Ohyama H, Kakihana M, Okamura H, Nakasho K: Transdifferentiation into
biliary ductular cells of hepatocytes transplanted into the spleen.
Pathology 2008, 40:272-276.
7. Desmet V, Roskams T, Van Eyken P: Ductular reaction in the liver. Pathol
Res Pract 1995, 191:513-524.
8. Chen YK, Zhao XX, Li JG, Lang S, Wang YM: Ductular proliferation in liver
tissues with severe chronic hepatitis B: an immunohistochemical study.
World J Gastroenterology 2006, 12:1443-1446.
9. Limaye PB, Alarcón G, Walls AL, Nalesnik MA, Michalopoulos GK,
Demetris AJ, Ochoa ER: Expression of specific hepatocyte and
cholangiocyte transcription factors in human liver disease and
embryonic development. Lab Invest 2008, 88:865-872.
10. Kanz MF, Gunasena GH, Kaphalia L, Hammond DK, Syed YA: A minimally
toxic dose of methylene dianiline injures biliary epithelial cells in rats.
Toxicol Appl Pharmacol 1998, 150:414-426.
11. Kanz MF, Wang A, Campbell GA: Infusion of bile from methylene
dianiline-treated rats into the common bile duct injures biliary epithelial
cells of recipient rats. Toxicol Lett 1995, 78:165-171.
12. Duncan SA: Transcriptional regulation of liver development. Dev Dyn
2000, 219:131-142.
13. Zaret KS, Grompe M: Generation and regeneration of cells of the liver
and pancreas. Science 2008, 322:1490-1494.
14. Pontoglio M, Barra J, Hadchouel M, Doyen A, Kress C, Bach JP, Babinet C,
Yaniv M: Hepatocyte nuclear factor 1 inactivation results in hepatic
dysfunction, phenylketonuria, and renal Fanconi syndrome. Cell 1996,
84:575-585.
15. Li J, Ning G, Duncan SA: Mammalian hepatocyte differentiation requires
the transcription factor HNF-4alpha. Genes Dev 2000, 14:464-474.
16. Hayhurst GP, Strick-Marchand H, Mulet C, Richard AF, Morosan S,
Kremsdorf D, Weiss MC: Morphogenetic competence of HNF4 alpha-
deficient mouse hepatic cells. J Hepatol 2008, 49:384-395.
17. Coffinier C, Gresh L, Fiette L, Tronche F, Schütz G, Babinet C, Pontoglio M,
Yaniv M, Barra J: Bile system morphogenesis defects and liver
dysfunction upon targeted deletion of HNF1beta. Development 2002,
129:1829-1838.
18. Clotman F, Lannoy VJ, Reber M, Cereghini S, Cassiman D, Jacquemin P,
Roskams T, Rousseau GG, Lemaigre FP: The onecut transcription factor
HNF6 is required for normal development of the biliary tract.
Development 2002, 129:1819-1828.
19. Clotman F, Lemaigre FP: Control of hepatic differentiation by activin/
TGFbeta signaling. Cell Cycle 2006, 5:168-171.
20. Clotman F, Jacquemin P, Plumb-Rudewiez N, Pierreux CE, Van der
Smissen P, Dietz HC, Courtoy PJ, Rousseau GG, Lemaigre FP: Control of
liver cell fate decision by a gradient of TGF beta signaling modulated by
Onecut transcription factors. Genes Dev 2005, 19:1849-1854.
21. Laconi E, Oren R, Mukhopadhyay DK, Hurston E, Laconi S, Pani P,
Dabeva MD, Shafritz DA: Long-term, near-total liver replacement by
transplantation of isolated hepatocytes in rats treated with retrorsine.
Am J Pathol 1998, 153:319-329.
22. Michalopoulos GK, DeFrances MC: Liver regeneration. Science 1997,
276:60-66.
23. Michalopoulos GK: Liver regeneration. J Cell Physiol 2007, 213:286-300.
24. del Castillo G, Alvarez-Barrientos A, Carmona-Cuenca I, Fernández M,
Sánchez A, Fabregat I: Isolation and characterization of a putative liver
progenitor population after treatment of fetal rat hepatocytes with TGF-
beta. J Cell Physiol 2008, 215:846-855.
25. Bisgaard HC, Nagy P, Santoni-Rugiu E, Thorgeirsson SS: Proliferation,
apoptosis, and induction of hepatic transcription factors are
characteristics of the early response of biliary epithelial (oval) cells to
chemical carcinogens. Hepatology 1996, 1:62-70.
Limaye et al. Comparative Hepatology 2010, 9:9
http://www.comparative-hepatology.com/content/9/1/9
Page 9 of 10
26. Zhou H, Rogler LE, Teperman L, Morgan G, Rogler CE: Identification of
hepatocytic and bile ductular cell lineages and candidate stem cells in
bipolar ductular reactions in cirrhotic human liver. Hepatology 2007,
45:716-724.
27. Petersen BE, Zajac VF, Michalopoulos GK: Bile ductular damage induced
by methylene dianiline inhibits oval cell activation. Am J Pathol 1997,
151:905-909.
28. Best DH, Coleman WB: Bile duct destruction by 4,4’-
diaminodiphenylmethane does not block the small hepatocyte-like
progenitor cell response in retrorsine-exposed rats. Hepatology 2007,
46:1611-1619.
29. Paku S, Nagy P, Kopper L, Thorgeirsson SS: 2-acetylaminofluorene dose-
dependent differentiation of rat oval cells into hepatocytes: confocal
and electron microscopic studies. Hepatology 2004, 39:1353-1361.
30. Cereghini S: Liver-enriched transcription factors and hepatocyte
differentiation. FASEB J 1996, 10:267-282.
31. Darlington GJ: Molecular mechanisms of liver development and
differentiation. Curr Opin Cell Biol 1999, 11:678-682.
32. Jacquemin P, Lannoy VJ, Rousseau GG, Lemaigre FP: OC-2, a novel
mammalian member of the ONECUT class of homeodomain
transcription factors whose function in liver partially overlaps with that
of hepatocyte nuclear factor-6. J Biol Chem 1999, 274:2665-2671.
33. Adachi M, Osawa Y, Uchinami H, Kitamura T, Accili D, Brenner DA: The
forkhead transcription factor FoxO1 regulates proliferation and
transdifferentiation of hepatic stellate cells. Gastroenterology 2007,
132:1434-1446.
doi:10.1186/1476-5926-9-9
Cite this article as: Limaye et al.: Expression of hepatocytic- and biliary-
specific transcription factors in regenerating bile ducts during
hepatocyte-to-biliary epithelial cell transdifferentiation. Comparative
Hepatology 2010 9:9.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Limaye et al. Comparative Hepatology 2010, 9:9
http://www.comparative-hepatology.com/content/9/1/9
Page 10 of 10
